2023
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
El Zarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T, Rubinstein P, Nonato T, McKay R, Li M, Mittra A, Owen D, Baiocchi R, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah N, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner M, Drakaki A, Baena J, Nebhan C, Haykal T, Morse M, Cortellini A, Pinato D, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs R, Funchain P, Saleem R, Woodford R, Long G, Menzies A, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid E, Chiao E, Sharon E, Johnson D, Ramaswami R, Bower M, Emu B, Marron T, Choueiri T, Baden L, Lurain K, Sonpavde G, Naqash A. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. Journal Of Clinical Oncology 2023, 41: 3712-3723. PMID: 37192435, PMCID: PMC10351941, DOI: 10.1200/jco.22.02459.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsProgression-free survivalObjective response rateOverall survivalMetastatic NSCLCCheckpoint inhibitorsGrade immune-related adverse eventsImmune checkpoint inhibitor trialsNeck squamous cell carcinomaActivity of ICICheckpoint inhibitor trialsCohort of PWHImmune checkpoint inhibitorsHIV viral loadKaplan-Meier methodSquamous cell carcinomaUse of ICIMean survival timeMost common cancersL1 monotherapyRECIST 1.1Adverse eventsInhibitor trialsMedian ageAdvanced cancer
2022
Impact of HIV infection on clinical outcomes among people diagnosed with head and neck cancer.
Salahuddin S, Cohen O, Wu M, Irizarry J, Vega T, Gan G, Deng Y, Isaeva N, Schalper K, Mehra S, Yarbrough W, Emu B. Impact of HIV infection on clinical outcomes among people diagnosed with head and neck cancer. Journal Of Clinical Oncology 2022, 40: e18080-e18080. DOI: 10.1200/jco.2022.40.16_suppl.e18080.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaCD8 T cell infiltrationPD-L1 expressionUninfected patientsT cell infiltrationPoor outcomeHNC patientsInsurance statusRace/ethnicityMedian survivalQuantitative immunofluorescenceIndependent predictorsClinical outcomesViral loadCell infiltrationNeck cancerAnatomic sitesTobacco useMultivariate analysisLow PD-L1 expressionCombination antiretroviral therapy eraTumor microenvironmentAntiretroviral therapy eraMedian CD4 countHIV viral load
2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study
Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang C, Yarchoan R, Cheever MA. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study. JAMA Oncology 2019, 5: 1332-1339. PMID: 31154457, PMCID: PMC6547135, DOI: 10.1001/jamaoncol.2019.2244.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaSafety of pembrolizumabB-cell lymphoproliferationCells/μLAntiretroviral therapyTumor responseKaposi's sarcomaStable diseaseCD4 countAdverse eventsAdvanced cancerMost treatment-emergent adverse eventsAdverse Events grade 2Anti-PD-1 therapyNCI Common Terminology CriteriaTreatment-emergent adverse eventsActive immunosuppressive therapyCommon Terminology CriteriaGood tumor responseT-cell countsAlanine aminotransferase levelsHIV viral loadPhase 1 studyImmune-related eventsCopies/mLPhase I study of pembrolizumab in people with HIV and cancer.
Uldrick T, Goncalves P, Abdul Hay M, Claeys A, Emu B, Ernstoff M, Fong L, Kaiser J, Kohrt H, Lacroix A, Lee S, Lundgren L, Lurain K, Parsons C, Peeramsetti S, Ramaswami R, Sharon E, Wang C, Yarchoan R, Cheever M. Phase I study of pembrolizumab in people with HIV and cancer. Journal Of Clinical Oncology 2019, 37: 2500-2500. DOI: 10.1200/jco.2019.37.15_suppl.2500.Peer-Reviewed Original ResearchAdverse eventsNon-Hodgkin lymphomaAntiretroviral therapyViral loadClinical benefitAnti-PD-1/PD-L1 therapyCD4 cells/μL.Elevated AST/ALTMedian age 57 yearsMulticenter phase 1 trialTreatment-emergent adverse eventsEmergent adverse eventsHBV/HCVSquamous cell skinPD-L1 therapyAge 57 yearsHIV viral loadAST/ALTPhase 1 trialCells/Cells/μL.Multicentric Castleman's diseaseAppropriate eligibility criteriaImmuno-oncology studiesNumber of cancers